0000950170-23-063121.txt : 20231113
0000950170-23-063121.hdr.sgml : 20231113
20231113171545
ACCESSION NUMBER: 0000950170-23-063121
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231108
FILED AS OF DATE: 20231113
DATE AS OF CHANGE: 20231113
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brannan Stephen K.
CENTRAL INDEX KEY: 0001777631
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38958
FILM NUMBER: 231400051
MAIL ADDRESS:
STREET 1: C/O KARUNA THERAPEUTICS, INC.
STREET 2: 33 ARCH STREET, SUITE 3110
CITY: BOSTON
STATE: MA
ZIP: 02110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Karuna Therapeutics, Inc.
CENTRAL INDEX KEY: 0001771917
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 270605902
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HIGH STREET
STREET 2: 26TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 857-449-2244
MAIL ADDRESS:
STREET 1: 99 HIGH STREET
STREET 2: 26TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
ownership.xml
4
X0508
4
2023-11-08
false
0001771917
Karuna Therapeutics, Inc.
KRTX
0001777631
Brannan Stephen K.
C/O KARUNA THERAPEUTICS, INC.
99 HIGH STREET, 26TH FLOOR
BOSTON
MA
02110
true
Chief Medical Officer
true
Common Stock
2023-11-08
4
M
false
2500
5.45
A
33650
D
Common Stock
2023-11-08
4
M
false
5000
131.64
A
38650
D
Common Stock
2023-11-08
4
S
false
1281
174.11
D
37369
D
Common Stock
2023-11-08
4
S
false
401
175.69
D
36968
D
Common Stock
2023-11-08
4
S
false
265
177.14
D
36703
D
Common Stock
2023-11-08
4
S
false
808
178.90
D
35895
D
Common Stock
2023-11-08
4
S
false
2245
180.08
D
33650
D
Option (right to buy)
5.45
2023-11-08
4
M
false
2500
0
D
2027-06-01
Common Stock
2500
14677
D
Option (right to buy)
131.64
2023-11-08
4
M
false
5000
0
D
2031-02-22
Common Stock
5000
31350
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.53 to $174.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (6) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.58 to $175.80, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.83 to $177.44, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.45 to $179.32, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.57 to $180.25, inclusive.
This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter.
This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of February 23, 2021, with additional vesting as to 6.25% of the shares underlying the option award at the end of each three month period thereafter.
/s/ Mia Kelley, Attorney-in-Fact
2023-11-13